Diplomat Pharmacy (Diplomat Pharmacy) Cash And Cash Equivalents : $8 Mil (As of Sep. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Diplomat Pharmacy Cash And Cash Equivalents?

Diplomat Pharmacy's quarterly cash and cash equivalents increased from Mar. 2019 ($2.74 Mil) to Jun. 2019 ($5.77 Mil) and increased from Jun. 2019 ($5.77 Mil) to Sep. 2019 ($8.42 Mil).

Diplomat Pharmacy's annual cash and cash equivalents increased from Dec. 2016 ($7.95 Mil) to Dec. 2017 ($84.25 Mil) but then declined from Dec. 2017 ($84.25 Mil) to Dec. 2018 ($9.49 Mil).

Diplomat Pharmacy Cash And Cash Equivalents Historical Data

The historical data trend for Diplomat Pharmacy's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diplomat Pharmacy Cash And Cash Equivalents Chart

Diplomat Pharmacy Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Cash And Cash Equivalents

Get a 7-Day Free Trial

17.96

27.60

7.95

84.25

9.49

Diplomat Pharmacy Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Cash And Cash Equivalents	Get a 7-Day Free Trial															8.21	9.49	2.74	5.77	8.42

Diplomat Pharmacy Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Diplomat Pharmacy (NYSE:DPLO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Diplomat Pharmacy Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Diplomat Pharmacy's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Diplomat Pharmacy (Diplomat Pharmacy) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Diplomat Pharmacy Inc (NYSE:DPLO) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

N/A

Address

4100 South Saginaw Street, Flint, MI, USA, 48507

Website

http://www.diplomat.is

Diplomat Pharmacy Inc. is active in the U.S. healthcare sector. It provides specialty pharmacy and infusion services, including pharmacy solutions for chronic diseases. The company has two main segments: specialty pharmacy and pharmacy benefit management. Its specialty pharmacy segment offers solutions to dispense, deliver, and dose prescription drugs. The pharmacy benefit management segment offers services to help control pharmacy benefit dollars and maximize quality of care. It derives most of its revenue through prescription drug sales in the United States.

Executives

Brian T Griffin	director, officer: Chairman and CEO
David C Dreyer	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Shawn Tomasello	director	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Regina M. Benjamin	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Benjamin Wolin	director	C/O EVERYDAY HEALTH, INC., 345 HUDSON STREET, 16TH FLOOR, NEW YORK NY 10014
Jeffrey G Park	director	C/O DIPLOMAT PHARMACY, INC., 4100 S. SAGINAW ST., FLINT MI 48507
Sean Whelan	director, officer: Chief Financial Officer	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Jeffrey M Rowe	director, officer: EVP of Operations	C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018